Current Report Filing (8-k)
April 17 2014 - 3:48PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
Date of Report (Date of Earliest Event Reported):
|
|
April 14, 2014
|
OPKO Health, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
001-33528
|
75-2402409
|
_____________________
(State or other jurisdiction
|
_____________
(Commission
|
______________
(I.R.S. Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
|
|
4400 Biscayne Blvd., Miami, Florida
|
|
33137
|
_________________________________
(Address of principal executive offices)
|
|
___________
(Zip Code)
|
|
|
|
Registrants telephone number, including area code:
|
|
(305) 575-4100
|
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 14, 2014, the Compensation Committee of the Board of Directors (the Committee)
of OPKO Health, Inc. (the Company) held a meeting to review certain compensation matters for the
Companys executive officers and non-executive employees. At the meeting, the Committee granted
stock options to the Companys named executive officers to purchase the number of shares of the
Companys common stock set forth opposite their name below. The stock options vest ratably over
four years and expire on the tenth anniversary of the grant date.
Phillip Frost, M.D.
CEO & Chairman of the Board
400,000
Jane H. Hsiao
Vice Chairman & Chief Technical Officer
350,000
Steven D. Rubin
Executive Vice President Administration
350,000
Adam Logal
Sr. Vice President, Chief Financial Officer
250,000
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
OPKO Health, Inc.
|
|
|
|
|
|
April 16, 2014
|
|
By:
|
|
Steven D. Rubin
|
|
|
|
|
|
|
|
|
|
Name: Steven D. Rubin
|
|
|
|
|
Title: Executive VP - Administration
|
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024